PURCHASE NON-MEMBER TICKETS HERE
AGENDA:
8:30AM
Breakfast and Registration
9:00AM
Hypnotics: David Neubauer, M.D.
10:00AM
Medical Cannabis and Cannabis Use Disorders: George Kolodner, M.D. & Sunil Khushalani, M.D.
11:00AM
Break
11:15AM
Optimizing Safe and Evidence-based Medication Treatment of Children & Adolescents: Gloria Reeves, M.D.
12:15PM
Lunch (Provided)
1:15PM
Update on the Psychopharmacology of Opioid Use Disorders: George Kolodner, M.D. & Sunil Khushalani, M.D.
2:15PM
Pharmacogenomic Testing for Psychiatrists: An Introduction: Francis Mondimore, M.D.
3:15PM
Break
3:30PM
Update on the Psychopharmacology of Alcohol Use Disorders: George Kolodner, M.D. & Sunil Khushalani, M.D.
SPEAKERS:
David N. Neubauer, MD, is an Associate Professor of Psychiatry at the Johns Hopkins University School of Medicine and Associate Director of the Johns Hopkins Sleep Disorders Center. He is a Fellow of the American Academy of Sleep Medicine and Life Fellow of the American Psychiatric Association. He is a member of the Sleep Research Society. He has written numerous journal articles and book chapters on sleep related topics. Dr. Neubauer was appointed by the American Psychiatric Association as liaison to the National Sleep Foundation Sleep Time Recommendations project. He currently serves on the National Sleep Foundation Board of Directors.
George Kolodner, MD, is an addiction psychiatrist who specializes in the outpatient treatment of substance use disorders. After leaving the Navy in 1973, he designed and implemented the first intensive outpatient addiction treatment program in the country – Kolmac Outpatient Recovery Centers – where he continues to serve as the medical director.
Sunil Khushalani, MD, is an addiction psychiatrist who specializes in treating patients who suffer from co-occurring psychiatric and addiction issues. Dr. Khushalani serves as the service chief of the Co-Occurring Disorders unit and the Adult Day Hospital at Sheppard Pratt. The co-occurring disorders program offers an integrated approach that treats both the addiction and mental health issues simultaneously.
Gloria Reeves, MD, is a child and adolescent psychiatrist at The University of Maryland. Dr. Reeves partnered with pharmacists, child mental health experts, and child-serving state agency leadership to help develop an antipsychotic medication prior authorization program for publicly-insured youth <18 years old. She currently serves as Medical Director of this program, and also serves as Medical Director of the Strive for Wellness program.
Francis Mondimore, M.D. is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins and is the director of the Mood Disorders Clinic at the Johns Hopkins Bayview Medical Center. Here, in conjunction with the National Network of Depression Centers, the clinical and research team is investigating the longitudinal course of serious depression and bipolar disorder in order to determine what constitute “best practices” for the care of individuals with these illnesses.
GOALS/OBJECTIVES:
At the end of this educational activity, the learner will be able to:
- Review key elements in evaluating insomnia
- Discuss broad approaches to treating insomnia
- List four major categories of substances people take to promote sleep
- Describe primary pharmacodynamic and pharmacokinetic properties of FDA-approved insomnia medications
- Increase familiarity with the medical benefits and potential dangers of cannabis
- Improve ability to use medications in the treatment of opioid use disorders
- Improve ability to use medications in the treatment of alcohol use disorder
- Become familiar with using pharmacogenomic testing to aid in selecting psychiatric medications
- Review current FDA approved indications for pediatric antipsychotic treatment and risk-to-benefit considerations in treatment with these medications in young patients